Attune Xenith Flow Cytometer

REQUEST FOR QUOTATION (RFQ) / COMBINED SYNOPSIS-SOLICITATION Solicitation Number: NIH-RFQ-26-PCA-NCI-02843 Notice Type: Combined Synopsis/Solicitation Title: Attune Xenith Flow Cytometer or Equal Posted Date: July 16, 2026 Response Date: July 21, 2026, 11:00 AM Eastern Time Set-Aside: None NAICS Code: 334516 – Analytical Laboratory Instrument Manufacturing PSC Code: 6640 – Laboratory Equipment and Supplies 1. GENERAL INFORMATION This is a combined synopsis/solicitation for commercial products prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice, and in conjunction with FAR Part 12. This announcement constitutes the only solicitation; quotations are being requested and a separate written solicitation will not be issued. The National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Pediatric Oncology Branch (POB), intends to acquire one (1) spectral flow cytometry system, including automation, software, installation, startup, training, warranty, and manufacturer-supported service, in accordance with the requirements set forth herein. This acquisition is being conducted as an open market purchase. The Government intends to award a Firm-Fixed-Price Purchase Order resulting from this solicitation. 2. DESCRIPTION OF REQUIREMENT 2.1 Background The Pediatric Oncology Branch conducts laboratory, translational, and clinical research focused on developing new therapies for children and young adults with cancer, including CAR-T, TCR-engineered, NK-cell, ?d T-cell, and other immune-based treatments. The Government requires replacement of an existing BD Fortessa flow cytometer, which is approaching end-of-life status, with a modern spectral flow cytometry platform capable of advanced immune cell analysis and characterization of patient-derived samples. The instrument will serve as a shared resource supporting six Pediatric Oncology Branch laboratories and multiple ongoing NIH intramural research studies. 2.2 Objective The objective of this acquisition is to obtain a commercial spectral flow cytometry system capable of supporting advanced immunophenotyping and functional immune cell analysis of patient-derived and preclinical samples, while providing high throughput, automation, and compatibility with existing laboratory workflows. 3. SALIENT CHARACTERISTICS / MINIMUM REQUIREMENTS The Government seeks one (1) Thermo Fisher Invitrogen Attune Xenith Flow Cytometer or equal. To be considered for award, any quoted product must meet all of the following minimum salient characteristics: 3.1 Instrument Requirements The system shall: Support spectral flow cytometry capability with full-spectrum fluorescence detection and spectral unmixing. Support conventional compensation-based flow cytometry workflows. Include a minimum of six excitation lasers, including: ultraviolet (UV), violet, blue, yellow-green, red, and near-infrared (NIR). Include a minimum of 51 fluorescent detectors and 6 scatter detectors. Utilize acoustic-assisted hydrodynamic focusing technology. Provide high-speed sample acquisition suitable for shared-resource operation. Be capable of analyzing tumor, tissue, blood, and cellular therapy samples. Be compatible with an automated sample loading system capable of processing both 96-well and 384-well plate formats. Include the CytKick Max Automated Sample Loader, or an equal automated sample loading system fully compatible with the quoted instrument and capable of equivalent functionality. Include integrated instrument control and analysis software for: instrument control, data acquisition, spectral analysis, quality control monitoring, and data export. Include touchscreen operation and automated maintenance functions. Provide remote diagnostics and manufacturer-supported service support. Include all hardware, software, licenses, accessories, and components necessary for complete and fully functional operation. 3.2 Ser...